Physician profile
Patrick J Scott
NPI 1376842559
$874.19
in general payments reported to CMS, 2019-2025
14 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.13 · 2020: $137 · 2021: $212 · 2022: $102 · 2023: $13.94 · 2024: $70.37 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $252.04 | 2020-2025 | Hydrus Microstent, Tryptyr, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $223.40 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $88.47 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $82.54 | 2022-2025 | Vyzulta |
| Sun Pharmaceutical Industries INC. | $50.49 | 2019-2020 | |
| Astellas Pharma US INC | $34.53 | 2024 | Izervay |
| Mallinckrodt Hospital Products INC. | $25.15 | 2025 | Acthar |
| Thea Pharma INC. | $20.24 | 2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $19.98 | 2019 | |
| Abbvie INC. | $17.99 | 2022 | |
| Glaukos Corporation | $16.75 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $16.17 | 2025 | Xdemvy |
| Allergan, INC. | $13.28 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.